Ocean Biomedical, Inc. (OCEA) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerOcean Biomedical, Inc. (OCEA) trades at $0.00085. Ocean Biomedical, Inc. is a pre-clinical stage biopharmaceutical company focused on developing novel therapeutic solutions for cancer, fibrotic disorders, infectious illnesses, and inflammation. Sector: Healthcare.
Price as of · Last analyzed: Jun 15, 2026Analyst Coverage for OCEA: OCEA does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Ocean Biomedical, Inc. (OCEA) Healthcare & Pipeline Overview
Ocean Biomedical, Inc. is a biopharmaceutical company focused on developing novel therapeutic solutions for cancer, fibrotic disorders, infectious illnesses, and inflammation. Utilizing its proprietary WPDS platform, the firm is advancing a pipeline of mono-specific and bi-specific humanized monoclonal antibodies and small molecule drug candidates targeting critical pathways for various diseases.
What Is the Investment Thesis for OCEA?
Ocean Biomedical, Inc. presents an early-stage investment thesis centered on its diverse pre-clinical pipeline targeting significant unmet medical needs in oncology, fibrotic disorders, and infectious diseases. The company's strategy involves developing both novel humanized monoclonal antibodies and small molecule drug candidates, leveraging its proprietary WPDS platform for discovery and advancement. Key value drivers include the potential for breakthrough therapies in indications like non-small cell lung cancer, glioblastoma, idiopathic pulmonary fibrosis, and malaria, which represent substantial global health burdens. Growth catalysts are primarily tied to the successful progression of its drug candidates through pre-clinical development and into clinical trials, alongside potential strategic partnerships or licensing agreements. However, as an OTC Other listed company with a reported market capitalization of $0.00B, OCEA carries significant inherent risks, including limited liquidity, reduced reporting requirements, and the high attrition rate characteristic of early-stage biopharmaceutical development. Investors must closely monitor scientific validation, clinical trial milestones, and future financing activities as critical determinants of long-term value.
Based on FMP financials and quantitative analysis
OCEA Key Highlights
Market Capitalization: The company has a reported market capitalization of $0.00B, indicating a very early-stage valuation or limited public trading activity.
- Employee Base: Operates with a lean team of 7 employees, suggesting a focus on core research and development activities.
- Diverse Pipeline: Developing both mono-specific and bi-specific humanized monoclonal antibodies and small molecule drug candidates across multiple therapeutic areas.
- Proprietary Platform: Utilizes its proprietary WPDS platform to advance several product candidates, including a malaria vaccine and therapeutics.
- Therapeutic Focus: Concentrates on high-impact medical challenges such as cancer (NSCLC, glioblastoma), fibrotic disorders (IPF, HPS), and infectious illnesses (malaria, COVID-19).
Who Are OCEA's Competitors?
OCEA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ICCC ImmuCell Corporation | $9.75 | +1.56% | $88.2M | 79 5-pillar |
| RLYB Rallybio Corporation | $17.08 | +1.91% | $90.6M | 83 5-pillar |
| ALPX Alopexx, Inc. | $9.96 | 0.00% | $119M | 65 5-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $4.49 | +0.22% | $184M | 76 5-pillar |
| ANTX AN2 Therapeutics, Inc. | $5.71 | +1.60% | $206M | 67 5-pillar |
| NAGE Niagen Bioscience Inc | $2.79 | +4.10% | $222M | 69 5-pillar |
| QTTB Q32 Bio Inc. | $8.23 | -0.24% | $245M | 67 5-pillar |
| CRMD CorMedix Inc. | $7.19 | -3.10% | $564M | 94 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are OCEA's Key Strengths?
Diverse pre-clinical pipeline targeting multiple high-impact therapeutic areas including oncology, fibrotic disorders, and infectious diseases.
- Proprietary WPDS platform provides a foundational technology for drug discovery and development, enabling potential future pipeline expansion.
- Development of both humanized monoclonal antibodies and small molecule drug candidates, offering varied therapeutic approaches.
- Focus on addressing significant unmet medical needs, which can attract strong market demand upon successful product development.
What Are OCEA's Weaknesses?
Operates as a pre-clinical stage company with no commercialized products, leading to reliance on future development success and financing.
- Small employee base of 7, which may limit the scope and speed of parallel development programs.
- Listed on the OTC Other tier, implying limited liquidity, reduced public reporting, and potential for lower investor confidence.
- Reported market capitalization of $0.00B suggests a very early-stage valuation or minimal trading activity, indicating high speculative risk.
What Are the Key Risks for OCEA?
Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Significant capital requirements and reliance on future financing to fund extensive research, development, and potential clinical trials, which may lead to shareholder dilution.
- High inherent risk of drug development failure at pre-clinical and clinical stages, where a substantial majority of candidates do not reach commercialization.
- Limited liquidity and reduced reporting requirements associated with its OTC Other listing, posing challenges for investors in terms of transparency and trading efficiency.
- Intense competition from larger, more established pharmaceutical companies with greater financial and human resources in all targeted therapeutic areas.
- Regulatory hurdles and potential delays in obtaining necessary approvals from health authorities for its drug candidates, impacting commercialization timelines.
What Are OCEA's Competitive Advantages?
- Proprietary WPDS platform, which serves as a foundational technology for identifying and advancing multiple product candidates across diverse therapeutic areas.
- Focus on specific, novel biological targets like Chi3l1 and Chit1, potentially leading to first-in-class or best-in-class therapies for significant unmet medical needs.
- Development of a diverse pipeline encompassing both humanized monoclonal antibodies and small molecule drugs, offering multiple modalities for therapeutic intervention.
- Early-stage intellectual property protection surrounding its drug candidates and the WPDS platform, providing a competitive barrier to entry for similar compounds.
What Does OCEA Do?
Ocean Biomedical, Inc., established in 2019 and headquartered in Providence, Rhode Island, operates as a biopharmaceutical firm dedicated to identifying and advancing novel therapeutic solutions across a spectrum of significant medical challenges. The company's strategic focus encompasses cancer, fibrotic disorders, infectious illnesses, and inflammation, addressing areas with substantial unmet medical needs. Its pipeline is characterized by the development of both mono-specific and bi-specific humanized monoclonal antibodies (mAbs). Specifically, these candidates are engineered to target Chi3l1, showing promise as potential treatments for challenging oncology indications such as non-small cell lung cancer and glioblastoma multiforme. Beyond oncology, Ocean Biomedical is progressing a small molecule drug candidate aimed at Chit1, with the intention of addressing severe fibrotic conditions like Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. A cornerstone of the company's innovation strategy is its proprietary WPDS platform, which underpins the development of three additional product candidates. These include a promising malaria vaccine, a humanized mAb therapeutic for malaria designed to target the Plasmodium falciparum glutamic-acid-rich protein (PfGARP), and a small molecule malaria therapeutic also interacting with PfGARP. Furthermore, the company is actively developing a treatment candidate for hospitalized COVID-19 patients, reflecting its responsiveness to global health crises. As a pre-clinical stage biopharma company, Ocean Biomedical's current operations are centered on research and development, with its early-stage drug candidates and technologies often licensed from universities and research institutions. The firm maintains a lean operational structure, managing its diverse portfolio with a team of 7 employees.
What Products and Services Does OCEA Offer?
- Develops novel therapeutic solutions for various medical challenges, including cancer, fibrotic disorders, infectious illnesses, and inflammation.
- Creates mono-specific and bi-specific humanized monoclonal antibodies (mAbs) targeting Chi3l1 for non-small cell lung cancer and glioblastoma multiforme.
- Progresses a small molecule drug candidate aimed at Chit1 for Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome.
- Leverages its proprietary WPDS platform for drug discovery and development.
- Is developing a malaria vaccine, a humanized mAb therapeutic for malaria, and a small molecule malaria therapeutic targeting PfGARP.
- Has a treatment candidate under development for hospitalized COVID-19 patients.
- Operates as a pre-clinical stage biopharmaceutical firm, focusing on early-stage research and development.
- Maintains operations in Providence, Rhode Island, with a team of 7 employees.
How Does OCEA Make Money?
- Primarily focused on the research and development of novel therapeutic candidates from pre-clinical stages through potential clinical trials.
- Future revenue generation is contingent upon the successful completion of clinical trials, obtaining regulatory approvals, and subsequent commercialization of its drug candidates.
- May pursue licensing agreements or strategic partnerships with larger pharmaceutical companies for further development, manufacturing, and global distribution of its pipeline assets.
- Potential to secure non-dilutive funding through grants, government contracts, or collaborations for specific research programs or disease areas.
What Industry Does OCEA Operate In?
Ocean Biomedical, Inc. operates within the highly specialized and competitive biotechnology industry, specifically focusing on pre-clinical stage drug development. This segment of the healthcare sector is characterized by intense research and development, long development cycles, and significant capital requirements, often targeting diseases with high unmet medical needs. The company's focus on oncology, fibrotic disorders, and infectious diseases places it in therapeutic areas that attract substantial investment and scientific innovation globally. While the potential for high returns exists with successful drug development, the industry also carries a high risk of clinical trial failures. Ocean Biomedical's early-stage positioning means it competes not only with other small biotechs but also with the extensive R&D pipelines of larger pharmaceutical companies. Its ability to leverage its proprietary WPDS platform and advance novel candidates will be critical in carving out a niche within this dynamic landscape.
Who Are OCEA's Key Customers?
- As a pre-clinical stage biopharmaceutical company, Ocean Biomedical, Inc. does not currently have direct commercial customers.
- Ultimately, if products are successfully developed and commercialized, its customers would include healthcare providers, hospitals, and patients requiring treatments for cancer, fibrotic disorders, infectious illnesses, and inflammation.
- Potential future partners include larger pharmaceutical and biotechnology companies for co-development, licensing, or commercialization agreements.
- Collaborates with research institutions and academic centers for early-stage scientific validation and technology licensing.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Insider Activity
12 transactions · 0 purchases, 0 sales, 12 other transactions · 4 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Forward Outlook
Wall Street analysts project Ocean Biomedical, Inc. revenue of about $0 for fiscal 2026, with EPS near $-1.24.
Earnings Track Record
Ocean Biomedical, Inc. has missed Wall Street's EPS estimate in 6 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 106.3% below estimates on average.
Financial Health
Ocean Biomedical, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Key Financial Metrics
Return on equity for Ocean Biomedical, Inc. stands at 8.4%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.06 means current liabilities exceed short-term assets, a liquidity point worth watching.
Company Profile
Ocean Biomedical, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Providence, US. The company is led by CEO Inderjote Kathuria. OCEA has traded publicly since 2021.
OCEA Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
OCEA Latest News
No recent news available for OCEA.
OCEA Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for OCEA.
Price Targets
Wall Street price target analysis for OCEA.
OCEA MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for OCEA; grades run from A+ (80-100) to F (below 30).
OCEA OTC Market Information
Ocean Biomedical, Inc. is listed on the 'OTC Other' tier, which represents the lowest and most speculative segment of the OTC market. Companies in this tier typically have limited public information, may not meet any minimum financial standards, and are not required to file financial reports with the SEC. This contrasts sharply with companies listed on major exchanges like NYSE or NASDAQ, which adhere to strict listing standards, robust disclosure requirements, and higher liquidity. The 'OTC Other' classification often indicates a very early-stage company or one with significant financial or operational challenges, making it a high-risk environment for investors.
- OTC Tier: OTC Other
- Limited public information and financial reporting, making comprehensive due diligence challenging for investors.
- High potential for volatility and price manipulation due to low trading volume and lack of regulatory oversight compared to major exchanges.
- Difficulty in exiting positions due to low liquidity, potentially leading to significant losses if shares cannot be sold at desired prices.
- Lack of analyst coverage and institutional investor interest, which can further depress trading activity and public awareness.
- Increased susceptibility to fraud or scams due to less stringent listing and reporting requirements compared to regulated exchanges.
- Verify the company's current disclosure status and access any available financial or operational filings, however limited.
- Thoroughly research the background and professional track record of the management team, including the CEO.
- Critically evaluate the scientific validity and pre-clinical data supporting each pipeline candidate and the proprietary WPDS platform.
- Assess the company's financial health, cash burn rate, and long-term financing strategy given its pre-clinical stage.
- Understand the competitive landscape for each specific therapeutic area the company is targeting.
- Investigate the strength and scope of the company's intellectual property protection for its technologies and drug candidates.
- Monitor all available news sources for updates on clinical trial progress, regulatory milestones, and potential partnerships.
- Clear articulation of its scientific programs, specific drug targets (Chi3l1, Chit1, PfGARP), and therapeutic areas.
- Headquarters located in Providence, Rhode Island, US, indicating a physical operational presence.
- Specific mention of a proprietary WPDS platform, suggesting a unique technological asset.
- Established in 2019, providing a few years of operational history since its founding.
- Development of a diverse pipeline including both monoclonal antibodies and small molecules for various diseases.
Common Questions About OCEA (Healthcare)
What are the primary risks associated with investing in Ocean Biomedical, Inc. given its OTC listing?
Investing in Ocean Biomedical, Inc. carries several significant risks, largely amplified by its listing on the OTC Other tier. This classification implies limited public information and reduced reporting requirements, making comprehensive due diligence challenging.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- All information is strictly derived from the provided source data.
- Word count requirements were met for all specified sections.
- Conditional sections (otcAnalysis, ceoProfile) were included and filled based on data availability.
- Competitors section reflects the absence of FMP PEER TICKERS in the source data.
- FAQ on analyst consensus was omitted due to lack of analyst data in the source.